Brokerages Expect TESARO, Inc. (TSRO) to Post -$1.19 EPS
Equities research analysts forecast that TESARO, Inc. (NASDAQ:TSRO) will announce earnings of ($1.19) per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for TESARO’s earnings. The highest EPS estimate is ($0.52) and the lowest is ($2.57). TESARO reported earnings of ($1.98) per share during the same quarter last year, which suggests a positive year over year growth rate of 39.9%. The business is scheduled to announce its next quarterly earnings report on Thursday, November 2nd.
On average, analysts expect that TESARO will report full year earnings of ($9.00) per share for the current fiscal year, with EPS estimates ranging from ($10.60) to ($8.04). For the next financial year, analysts anticipate that the firm will report earnings of ($5.07) per share, with EPS estimates ranging from ($7.63) to ($0.57). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow TESARO.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter in the previous year, the firm earned ($1.28) earnings per share. TESARO’s revenue was down 17.6% on a year-over-year basis.
Several research analysts recently issued reports on TSRO shares. Cann reissued a “buy” rating and set a $199.00 target price on shares of TESARO in a report on Monday, June 5th. Citigroup Inc. reiterated a “buy” rating and issued a $216.00 target price on shares of TESARO in a research report on Monday. Robert W. Baird reiterated a “neutral” rating and issued a $140.00 target price (down previously from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Cowen and Company dropped their target price on shares of TESARO from $145.00 to $124.00 and set a “market perform” rating on the stock in a research report on Monday, June 19th. Finally, Credit Suisse Group set a $190.00 price target on shares of TESARO and gave the stock a “buy” rating in a research report on Friday, August 18th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $175.15.
Shares of TESARO (NASDAQ TSRO) opened at 118.22 on Wednesday. The firm’s 50-day moving average is $123.15 and its 200-day moving average is $141.79. TESARO has a 52 week low of $91.76 and a 52 week high of $192.94. The stock’s market capitalization is $6.41 billion.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/13/brokerages-expect-tesaro-inc-tsro-to-post-1-19-eps.html.
In other news, VP Grant C. Bogle sold 14,167 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the transaction, the vice president now directly owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,100 shares of company stock valued at $3,387,465. 34.60% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Hanseatic Management Services Inc. boosted its holdings in shares of TESARO by 0.3% during the second quarter. Hanseatic Management Services Inc. now owns 5,936 shares of the biopharmaceutical company’s stock valued at $830,000 after acquiring an additional 15 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of TESARO by 2.1% during the first quarter. Teacher Retirement System of Texas now owns 2,945 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 60 shares during the period. Profund Advisors LLC boosted its holdings in shares of TESARO by 3.8% during the first quarter. Profund Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock valued at $394,000 after acquiring an additional 93 shares during the period. Stephens Inc. AR boosted its holdings in shares of TESARO by 6.5% during the second quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 115 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its holdings in shares of TESARO by 1.1% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 12,092 shares of the biopharmaceutical company’s stock valued at $1,690,000 after acquiring an additional 136 shares during the period.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.